EMA Opens Registry for Small and Medium Companies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Opens Registry for Small and Medium Companies


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency launched on December 20, 2010, a public registry about small and medium-sized enterprises (SME) that includes information about SME-registered companies. The goal is to facilitate interaction among these types of companies. For now the, website includes details such as company contact information, activities, and number of employees. In March 2011, according to an EMA press release, the registry will also include information about company products, including what’s in the pipeline. To be included in the registry, companies must be based in the European Economic Area and have submitted to the agency an SME declaration per the European Commission Directive 2003/361/EC.

“This initiative is in line with the overall transparency policy of the Agency,” says the EMA release. The idea is to provide more information to the pubic and, in turn, to increase support for the 20 million SMEs located throughout the European Union.

EMA also has a dedicated SME Office, which provides assistance to companies regarding the development and authorization of drug products. For example, the agency offers help with regulatory procedures, translations, fee reductions, exemptions, and deferrals, says the EMA release. There is also a helpful Question and Answer section on the new registry for SMEs needing more information.

See PharmTech related articles:
EMA Publishes New Transparency Policy (ePT)

EMA Criticized over Transparency Rules (ePT)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here